Cagrilintide is a long-acting amylin analog from Novo Nordisk, studied alone and together with semaglutide as CagriSema. It is not FDA approved as of October 2026.
Also known as: CagriSema (with semaglutide).
There is no approved cagrilintide product. Powder vials are usually labeled 5 mg or 10 mg.
Here is the math for a 5 mg vial mixed with 2 mL of bacteriostatic water, drawing 500 mcg with a U-100 insulin syringe (1 mL = 100 units).
5 mg ÷ 2 mL = 2.5 mg/mL500 mcg ÷ 2.5 mg/mL = 0.2 mL0.2 mL × 100 = 20 units| Amount | Volume | U-100 syringe |
|---|---|---|
| 250 mcg | 0.1 mL | 10 units |
| 500 mcg | 0.2 mL | 20 units |
| 1 mg | 0.4 mL | 40 units |
Adding more water doesn't change how much cagrilintide is in the vial. It only spreads it over more liquid, so each draw is bigger and easier to read.
| Water added | Concentration | Volume | U-100 syringe |
|---|---|---|---|
| 1 mL | 5 mg/mL | 0.1 mL | 10 units |
| 2 mL | 2.5 mg/mL | 0.2 mL | 20 units |
| 3 mL | 1.67 mg/mL | 0.3 mL | 30 units |
| 5 mL | 1 mg/mL | 0.5 mL | 50 units |
For any other vial size or amount, the free peptide reconstitution calculator works backwards from the amount you want and suggests a water volume that lands on a clean syringe mark.
A phase 1b trial (Enebo 2021) reported a half-life of roughly 159 to 195 hours (about 7 to 8 days). We could not confirm a time to peak, so we leave it out.
Numbers shown are the values Dose Track uses, listed only where they agree with the source above. Half-life varies from person to person and with injection site.